0000950170-24-125613 | 10-Q | XBRL Viewer

Consolidated Joint Venture	9 Months Ended
Sep. 30, 2024
Equity Method Investments and Joint Ventures [Abstract]
Consolidated Joint Venture	7. Consolidated Joint Venture In 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of September 30, 2024, the Company and Legacy hold 50.75% and 49.25% interests in Archipelago, respectively, and have made capital contributions to Archipelago of $3.1 million and $3.0 million, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Legacy’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. Refer to Note 1 for basis of presentation. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.

Consolidated Joint Venture

9 Months Ended

Sep. 30, 2024

Equity Method Investments and Joint Ventures [Abstract]

7. Consolidated Joint Venture

In 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii.

Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of September 30, 2024, the Company and Legacy hold 50.75% and 49.25% interests in Archipelago, respectively, and have made capital contributions to Archipelago of $3.1 million and $3.0 million, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal.

The Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. Legacy’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets. Refer to Note 1 for basis of presentation.

In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.

Related-Party Transactions	9 Months Ended
Sep. 30, 2024
Related Party Transactions [Abstract]
Related-Party Transactions	16. Related-Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, one of the Company’s largest stockholder, and the JSF share common officers and directors. JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $30,000 and $58,000 as of September 30, 2024 and December 31, 2023, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties.

Related-Party Transactions

9 Months Ended

Sep. 30, 2024

Related-Party Transactions

16. Related-Party Transactions

The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, one of the Company’s largest stockholder, and the JSF share common officers and directors.

JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $30,000 and $58,000 as of September 30, 2024 and December 31, 2023, respectively, and are included in the condensed consolidated balance sheets as amounts due to related parties.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Warrants and Options - Summary of Key Terms and Activity of Liability Classified Preferred Investment Options (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
March 2023 Options - Series A [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2023-03
Term	5 years
Exercise Price Per Share	$ 9
Exercised during the period	0	0
Outstanding	666,334		666,334
March 2023 Options - Series B [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2023-03
Term	1 year 6 months
Exercise Price Per Share	$ 9
Exercised during the period	0	0
Outstanding	0		666,334
March 2023 Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2023-03
Term	5 years
Exercise Price Per Share	$ 11.25
Exercised during the period	0	0
Outstanding	33,317		33,317
August 2022 Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise Price Per Share	$ 9
Exercised during the period	0	0
Outstanding	118,063		118,063
August 2022 Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Issuance Date	2022-08
Term	5 years
Exercise Price Per Share	$ 52.8
Exercised during the period	0	0
Outstanding	5,904		5,904
March 2023, August 2022 Options and Placement Agent Options [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercised during the period	0	0
Outstanding	823,618		1,489,952

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	1,301,010	1,840,967	1,301,010	1,840,967
Option to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	217,575	84,058	217,575	84,058
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	259,817	266,957	259,817	266,957
Preferred Investment Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	823,618	1,489,952	823,618	1,489,952

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (1,612,000)	$ (2,423,000)	$ (2,567,000)	$ (9,384,000)	$ (2,974,000)	$ (11,133,000)	$ (14,000,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant and option liabilities	(330,000)		(608,000)		(493,000)	(5,965,000)
Issuance and offering costs allocated to liability classified options	0		0		0	430,000
Valuation loss on March 2023 PIPE	0		0		0	6,076,000
Depreciation					92,000	227,000
Lease amortization					502,000	535,000
Amortization of note receivable discount					(90,000)	0
Gain on disposal of property and equipment					(65,000)	(36,000)
Gain on sale of RS durum wheat trait	0		0		(4,000,000)	0
Stock-based compensation	155,000		162,000		395,000	573,000
Write-down of inventories	154,000		252,000		154,000	444,000
Impairment of property and equipment		36,000			36,000	0
Changes in operating assets and liabilities:
Accounts receivable and other receivables					(445,000)	249,000
Inventories					620,000	(1,388,000)
Prepaid expenses and other current assets					287,000	(284,000)
Other noncurrent assets					0	(13,000)
Accounts payable and accrued expenses					(719,000)	(300,000)
Amounts due to related parties					(29,000)	(2,000)
Other current liabilities					(11,000)	11,000
Operating lease liabilities					(678,000)	(573,000)
Net cash used in operating activities					(7,418,000)	(11,149,000)	(15,300,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment					342,000	42,000
Proceeds from sale of Verdeca - earn-out received					0	569,000
Proceeds from sale of investments					2,501,000	0
Proceeds from sale of RS durum wheat trait					4,000,000	0
Cash paid related to sale of GoodWheat					(2,000,000)	0
Purchases of property and equipment					(16,000)	(5,000)
Purchases of investments					0	(5,002,000)
Net cash provided by (used in) investing activities					4,827,000	(4,396,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from ESPP purchases					9,000	12,000
Net cash provided by financing activities					9,000	5,512,000
Net decrease in cash and cash equivalents					(2,582,000)	(10,033,000)
Cash and cash equivalents - beginning of period		$ 6,518,000		$ 20,644,000	6,518,000	20,644,000	20,644,000
Cash and cash equivalents - end of period	$ 3,936,000		$ 10,611,000		3,936,000	10,611,000	$ 6,518,000
NONCASH INVESTING AND FINANCING ACTIVITIES:
Right of use assets obtained in exchange for new operating lease liabilities					86,000	0
Note receivable recognized from sale of GoodWheat					5,705,000	0
March 2023 PIPE [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, pre-funded warrants and preferred investment options from March 2023 PIPE					0	5,997,000
Payments of offering costs relating to March 2023 PIPE					0	(497,000)
NONCASH INVESTING AND FINANCING ACTIVITIES:
Common stock options issued to placement agent and included in offering costs					0	212,000
Warrant and option modifications included in Valuation loss on March 2023 PIPE					$ 0	$ 404,000

Income Taxes

9 Months Ended

Sep. 30, 2024

Income Tax Disclosure [Abstract]

Income Taxes

13. Income Taxes

Income tax expense during interim periods is based on applying an estimated annual effective income tax rate to year-to-date income, plus any significant unusual or infrequently occurring items that are recorded in the interim period. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and significant judgment including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in various jurisdictions, permanent and temporary differences, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, more experience is obtained, additional information becomes known, or as the tax environment changes.

The interim financial statement provision for income taxes is different from the amounts computed by applying the United States federal statutory income tax rate of 21%. The Company’s effective tax rate was 0.00% for each of the three and nine months ended September 30, 2024 and 2023. The difference between the effective tax rate and the federal statutory rate of 21% was primarily due to the full valuation allowance recorded on the Company’s net deferred tax assets.

During the nine months ended September 30, 2024, there were no material changes to the Company’s uncertain tax positions.

In February 2023, the Company received notification from the Internal Revenue Service ("IRS") that our Archipelago joint venture was selected for audit for the 2021 tax year. The Company received the IRS Notice of Proposed Partnership Adjustment during the third quarter of 2024 and accepted the adjustments. The Company is now awaiting the IRS Final Partnership Adjustment ("FPA"). Reception of the FPA will start a 45-day clock on making the push out election, to push the audit adjustments to the partners. Upon conclusion of the audit, Arcadia expects to adjust their balance of available tax net operating losses and have no penalties or interest due. The Company is currently not under audit for state purposes.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)					3 Months Ended		9 Months Ended
	Jun. 25, 2024 shares	Feb. 02, 2022 shares	May 20, 2015 shares	May 14, 2015	Sep. 30, 2024 USD ($) shares	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) IncentivePlan shares	Sep. 30, 2023 USD ($)	Dec. 31, 2023 shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans \| IncentivePlan							2
Shares Subject to Outstanding, Options granted							158,000
Total number of options outstanding					217,575		217,575		80,078
Unrecognized compensation cost related to unvested stock-based compensation grants \| $					$ 524,000		$ 524,000
Weighted-average remaining recognition period							1 year 4 months 24 days
Stock-based compensation \| $					$ 155,000	$ 162,000	$ 395,000	$ 573,000
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan					3,209		3,209
Stock-based compensation \| $					$ 2,000	$ 7,000	$ 6,000	$ 12,000
Percentage in payroll deductions to acquire shares of common stock				15.00%
Purchase plan offering period				6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage				85.00%
Issuance of common stock pursuant to employee stock purchase plan							8,073
First offering period, start date				May 14, 2015
First offering period, end date				Feb. 01, 2016
Inducement Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of options outstanding					6,949		6,949		8,366
Inducement Stock Option [Member] \| Stanley Jacot, Jr. [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Subject to Outstanding, Options granted		7,902
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan							The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan			3,860		338,248		338,248
Number of shares awarded o individual employee	50,000		9,375
Options vesting period			4 years
Additional shares authorized for issuance under the plan	200,000
Common stock available for future grant					127,725		127,725
Total number of options outstanding					210,523		210,523		71,609
2015 Omnibus Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period			10 years
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan			259
Total number of options outstanding					102		102		102

Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended						9 Months Ended		12 Months Ended
	Nov. 30, 2020	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	May 16, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Place of incorporation								Arizona
Year of incorporation								2002
Place of reincorporation								Delaware
Date of reincorporation								2015-03
Gain on sale of collaborative arrangements		$ 0			$ 0			$ 4,000,000	$ 0
Proceeds from sale of RS durum wheat trait								4,000,000	0
License revenue		1,537,000			1,298,000			3,829,000	3,677,000
Accumulated deficit		(274,814,000)						(274,814,000)		$ (271,840,000)
Cash and cash equivalents		3,936,000						3,936,000		6,518,000
Short-term investments		2,640,000						2,640,000		5,124,000
Current note receivable		1,827,000						1,827,000		0
Net losses		$ (1,612,000)	$ 1,061,000	$ (2,423,000)	$ (2,567,000)	$ 818,000	$ (9,384,000)	(2,974,000)	(11,133,000)	(14,000,000)
Net cash used in operations								$ 7,418,000	$ 11,149,000	15,300,000
Reverse stock split								In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock.
Additional shares of common stock of reverse stock split								19,118
Verdeca LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gain on sale of Verdeca											$ 1,100,000
Discontinued Operations [Member] \| GoodWheat [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of net consideration												$ 3,700,000
Collaborative Arrangements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gain on sale of collaborative arrangements								$ 4,000,000
Proceeds from sale of RS durum wheat trait								$ 4,000,000
Bioceres Crop Solutions [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License revenue											$ 862,000
Bioceres Crop Solutions [Member] \| Verdeca LLC [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional cash receivable from sale of interest in joint venture	$ 2,000,000
Payment received on accounts and other receivable										$ 2,000,000
Bioceres Crop Solutions [Member] \| Verdeca LLC [Member] \| Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash shares and royalty receivable	$ 10,000,000

Equity Financing

9 Months Ended

Sep. 30, 2024

Equity [Abstract]

Equity Financing

10. Equity Financing

March 2023 Private Placement

In March 2023, the Company issued in a private placement offering (the “March 2023 Private Placement”) pursuant to a securities purchase agreement (“March 2023 Purchase Agreement”) (i) 165,500 shares of its common stock, (ii) pre-funded common stock purchase warrants (the “March 2023 Pre-Funded Warrants”) to purchase up to 500,834 shares of common stock, at an exercise price of $0.0001 per share, (iii) Series A preferred investment options (the “March 2023 Options - Series A") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $9.00 per share, and (iv) Series B preferred investment options (the “March 2023 Options - Series B”, and together with the March 2023 Options - Series A, the "March 2023 Options") to purchase up to a total of 666,334 shares of common stock, at an exercise price of $9.00 per share, and raised total gross proceeds of $6.0 million. The March 2023 Private Placement closed on March 6, 2023. The March 2023 Pre-Funded Warrants became exercisable upon issuance and were fully exercised as of September 30, 2024. The March 2023 Options - Series A are exercisable at any time at the option of the holder and expire 5 years from the date of issuance. The March 2023 Options - Series B were exercisable at any time at the option of the holder and expire 1.5 years from the date of issuance. As of September 30, 2024, the March 2023 Options - Series B expired.

In connection with the March 2023 Private Placement, the Company entered into preferred investment option amendment agreements (the “Option Amendment Agreements”) with certain investors. Under the Option Amendment Agreements, the Company agreed to amend certain existing warrants and preferred investment options to purchase up to a total of 178,132 shares of common stock that were previously issued to the investors in September 2019, May 2020, July 2020, December 2020, January 2021 and August 2022, with exercise prices of $300.80, $191.00, $154.00, $120.00, $125.20 and $37.35 per share, respectively (the “Existing Warrants”). Under the Option Amendment Agreements, the Company agreed to lower the exercise price of the Existing Warrants to $9.00 per share. In addition, the Company granted to a placement agent preferred investment options to purchase a total of 33,317 shares of Common Stock (the “March 2023 Placement Agent Options”) that have an exercise price per share equal to $11.25 and a term of 5 years from the date of issuance. The re-pricing of the Existing Warrants resulted in an increase in fair value of $404,000, of which $185,000 of the increase in fair value was related to the August 2022 liability classified options. The increase in fair value related to the re-pricing of Existing Warrants was recognized in Valuation Loss on March 2023 PIPE on the condensed consolidated statements of operations and comprehensive loss.

The March 2023 Options and March 2023 Placement Agent Options are classified as liabilities within Level 3 due to certain early settlement provisions that preclude them from equity classification. The Company utilized the Black-Scholes Model on March 6, 2023 with the following assumptions for the Series A Investment Options: volatility of 128.55%, stock price of $7.61 and risk-free rate of 4.27%. The following assumptions were utilized for the Series B Investment Options: volatility of 103.33%, stock price of $7.61 and risk-free rate of 4.97%. The estimated fair value of the liability classified March 2023 Options issued was $6.6 million. The estimated fair value of the common stock option liabilities was subsequently remeasured at September 30, 2024 with the changes recorded on the Company’s condensed consolidated statements of operations and comprehensive loss.

The estimated fair value of the common stock issued and March 2023 Pre-Funded Warrants was $5.1 million. The total estimated fair value of the common stock issued, March 2023 Pre-Funded Warrants and March 2023 Options as of March 6, 2023 exceeded the gross proceeds of the March 2023 Private Placement by $5.7 million and this amount was recognized in Valuation Loss on March 2023 PIPE on the condensed consolidated statements of operations and comprehensive loss.

The March 2023 Placement Agent Options were issued for services performed by the placement agent as part of the March 2023 Private Placement and were treated as offering costs. The value of the March 2023 Placement Agent Options was determined to be $212,000, calculated using the Black-Scholes Model. The Company incurred additional offering costs totaling $548,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the March 2023 Private Placement. A total of $430,000 was allocated to the common stock option liabilities and expensed while the remaining $330,000 was allocated to the common stock and March 2023 Pre-Funded Warrants and offset to additional paid in capital.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Property and Equipment, Net - Additional Information (Detail) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Depreciation expense	$ 7,000		$ 89,000	$ 92,000	$ 227,000
Property and equipment classified as assets held for sale, fair value						$ 51,000
Impairment of property and equipment		$ 36,000		$ 36,000	$ 0

Note Receivable

9 Months Ended

Sep. 30, 2024

Receivables [Abstract]

Note Receivable

6. Note Receivable

On May 16, 2024, the Company sold the GoodWheat brand to Above Food for net consideration of $3.7 million. The assets sold consisted primarily of grain and finished goods inventories, formulations and trademarks. A loss of $1,500 was recognized in the condensed consolidated statements of operations and comprehensive loss during the nine months ended September 30, 2024, related to the sale.

In connection with the transaction, Arcadia paid to Above Food $2.0 million and received a $6.0 million promissory note dated May 14, 2024. The promissory note has a term of three years and accrues interest at the Wall Street Journal prime rate. On each of the first, second and third anniversaries of the promissory note, accrued interest and $2.0 million of principal are payable to Arcadia. The promissory note contains contingent features, including an option that requires Above Food to cause its parent entity, Above Food Ingredients Inc. (“Parent Company”), to issue to the Company publicly traded stock of Parent Company in exchange for the cancellation of a portion of the principal of the promissory note, as well as default provisions.

The Company accounted for the promissory note as a note receivable in accordance with ASC 310. The Company did not elect the fair value option and since the Company intends to and has the ability to hold the promissory note to maturity, it has been classified as held for investment and is reported on the condensed consolidated balance sheet at amortized cost. The first installment payment due in 2025 is classified as current and the remaining installment payments due in 2026 and 2027 are classified as noncurrent on the condensed consolidated balance sheet.

The contingent features of the promissory note were evaluated for bifurcation in accordance with ASC 815. The contingent features requiring bifurcation had an estimated fair value of $250,000 as of the transaction date and as of September 30, 2024. The estimated fair value of the contingent features is reported in note receivable – noncurrent on the condensed consolidated balance sheet as of September 30, 2024. The promissory note was recorded at a discount of $545,000, which is being amortized over the term of the promissory note using the effective interest method. The Company recognized discount amortization of $60,000 and $89,000 in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2024, respectively. The Company recognized accrued interest of $126,000 and $193,000 in the condensed consolidated statements of operations and comprehensive loss during the three and nine months ended September 30, 2024, respectively.

Warrants and Options - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Class Of Warrant Or Right [Line Items]
Exercised during the period	(75,000)	(482,647)
Outstanding	259,817		341,957
March 2023 Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2023-03
Term	perpetual
Exercise Price Per Share	$ 0
Exercised during the period	(75,000)	(425,834)
Outstanding	0		75,000
December 2022 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-12
Term	5 years
Exercise Price Per Share	$ 11.2
Exercised during the period	0	0
Outstanding	1,000		1,000
October 2022 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-10
Term	5 years
Exercise Price Per Share	$ 16
Exercised during the period	0	0
Outstanding	1,000		1,000
August 2022 Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2022-08
Term	perpetual
Exercise Price Per Share	$ 0
Exercised during the period	0	(56,813)
Outstanding	0		0
January 2021 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 159.60
Exercised during the period	0	0
Outstanding	9,846		9,846
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 9
Exercised during the period	0	0
Outstanding	16,367		16,367
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 120.00
Exercised during the period	0	0
Outstanding	49,100		49,100
December 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years
Exercise Price Per Share	$ 152.80
Exercised during the period	0	0
Outstanding	3,274		3,274
July 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 9.00
Exercised during the period	0	0
Outstanding	16,036		16,036
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 198.80
Exercised during the period	0	0
Outstanding	802		802
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 9
Exercised during the period	0	0
Outstanding	9,946		9,946
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 191.20
Exercised during the period	0	0
Outstanding	24,863		24,863
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 245.20
Exercised during the period	0	0
Outstanding	1,741		1,741
September 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years
Exercise Price Per Share	$ 379.20
Exercised during the period	0	0
Outstanding	0		1,649
June 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years
Exercise Price Per Share	$ 251.60
Exercised during the period	0	0
Outstanding	0		1,862
April 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-04
Term	5 years
Exercise Price Per Share	$ 247.20
Exercised during the period	0	0
Outstanding	0		3,629
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 125.2
Exercised during the period	0	0
Outstanding	90,629		90,629
January 2021 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2021-01
Term	5 years 6 months
Exercise Price Per Share	$ 9
Exercised during the period	0	0
Outstanding	7,831		7,831
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 300.8
Exercised during the period	0	0
Outstanding	6,594		6,594
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 9
Exercised during the period	0	0
Outstanding	9,892		9,892
June 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years 6 months
Exercise Price Per Share	$ 200
Exercised during the period	0	0
Outstanding	10,896		10,896

Leases (Tables)

9 Months Ended

Sep. 30, 2024

Lessee Disclosure [Abstract]

Schedule of Leases

Leases consisted of the following (in thousands):


Leases	Classification	September 30, 2024		December 31, 2023
Assets
Operating lease assets	Right of use asset	$	306	$	792
Total leased assets		$	306	$	792
Liabilities
Current - Operating	Operating lease liability- current	$	346	$	852
Noncurrent - Operating	Operating lease liability- noncurrent		—		155
Total leased liabilities		$	346	$	1,007


Lease Cost	Classification	Three Months Ended September 30, 2024			Three Months Ended September 30, 2023			Nine Months Ended September 30, 2024			Nine Months Ended September 30, 2023
Operating lease cost	SG&A and R&D Expenses	$	172		$	191		$	678		$	572
Short term lease cost	SG&A Expenses		3			3			10			10
Sublease income (1)	SG&A and R&D Expenses		(142	)		(111	)		(404	)		(329	)
Net lease cost		$	33		$	83		$	284		$	253

(1)

Sublease income is recorded as a reduction to lease expense.


Lease Term and Discount Rate	September 30, 2024			December 31, 2023
Weighted-average remaining lease term (years)		0.7			2.3
Weighted-average discount rate		6.5	%		6.0	%

Inventory (Tables)

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Summary of Inventories

Inventories, net consist of the following (in thousands):


	September 30, 2024		December 31, 2023
Raw materials	$	450	$	373
Finished goods		385		660
Inventories	$	835	$	1,033

Description of Business and Basis of Presentation

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Description of Business and Basis of Presentation

1. Description of Business and Basis of Presentation

Organization

Arcadia Biosciences, Inc. (the "Company," "Arcadia" or "management"), was incorporated in Arizona in 2002 and maintains its headquarters in Dallas, Texas, with additional office space in Davis and Sacramento, California. The Company was reincorporated in Delaware in March 2015.

Since acquiring the assets of Live Zola, LLC ("Zola") in May 2021, the Company has provided consumers with a great tasting way to rehydrate, reset, and reenergize with Zola coconut water products. The company has leveraged its history as a leader in science-based approaches to develop high value products and drive innovation in the consumer goods industry. Previously, the Company developed products primarily in wheat, which it commercialized through the sales of seed, grain and food ingredients and products, and through trait licensing and royalty agreements.

On May 16, 2024, the Company sold the GoodWheat™ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 for details of the transaction.

On May 14, 2024, the Company sold its non-GMO Resistant Starch ("RS") durum wheat trait to longtime partner Corteva AgriScience ("Corteva"). Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction. Refer to Note 8 for details of the partnership and transaction.

In May 2021, the Company’s wholly owned subsidiary Arcadia Wellness, LLC (“Arcadia Wellness” or “AW”) acquired the businesses of Eko Holdings, LLC, Lief, LLC, and Zola. The acquisition included Saavy Naturals™, a line of natural body care products, Soul Spring™, a CBD-infused botanical therapy brand in the natural category, and ProVault™, a THC-free CBD sports performance formula made with natural ingredients, providing effective support and recovery for athletes (collectively, "body care brands"). Also included in the purchase was Zola, a coconut water sourced exclusively with sustainably grown coconuts from Thailand. In July 2022, the Company entered into an agreement to license Saavy Naturals to Radiance Beauty and Wellness, Inc. ("Radiance Beauty"). In July 2023, management made the decision to exit the remaining body care brands, Soul Spring and ProVault, as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023.

In August 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 7) to grow, extract, and sell hemp products. The partnership Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. In October 2021, Arcadia and Legacy mutually agreed to wind down the cultivation activities of Archipelago, due to regulatory challenges and a saturated hemp market.

In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. In November 2020, Arcadia sold its membership interest in Verdeca to Bioceres in a transaction in which Arcadia received cash, shares of Bioceres stock and a royalty stream of up to $10.0 million on sales of Haab 4 soybeans (“HB4”). An additional $2.0 million in cash was to be paid to Arcadia upon Verdeca achieving commercial plantings of at least 200,000 hectares of HB4 or China approving the HB4 soybean trait for “food and feed”. During 2022, Bioceres received China's approval of the HB4 soybean trait and as a result, Arcadia recorded license revenue of $862,000 and a gain on sale of Verdeca of $1.1 million on the condensed consolidated statements of operations and comprehensive loss. The Company received the full payment of $2.0 million as of December 31, 2023.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, Arcadia Wellness, and Archipelago.

The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE.

For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. The non-controlling partner’s equity interests are presented as non-controlling interests on the condensed consolidated balance sheets.

The information included in these condensed consolidated financial statements and notes thereto should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included herein and Management’s Discussion and Analysis of Financial Condition and Results of Operations and the condensed consolidated financial statements and notes thereto for the fiscal year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K, filed with the SEC on March 28, 2024.

Reclassifications

Certain previously reported financial information has been reclassified to conform to the current year presentation. For a discussion of the reclassification of the financial presentation of our former GoodWheat and body care brands reported as discontinued operations, see “Discontinued Operations” section below. Unless otherwise noted, amounts and disclosures throughout these notes to condensed consolidated financial statements relate solely to continuing operations and exclude all discontinued operations.

Reverse Stock Split

In February 2023, the Company’s board of directors approved a reverse split of 40:1 on the Company’s issued and outstanding common stock. On February 15, 2023, the Company’s stockholders approved the certificate of amendment to the Company’s certificate of incorporation, which the Company filed on February 27, 2023 with the Secretary of State of Delaware to effect the reverse split on March 1, 2023. As a result of the reverse stock split, 19,118 additional shares of common stock were issued in lieu of fractional shares. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented.

Liquidity, Capital Resources, and Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity financings. As of September 30, 2024, the Company had an accumulated deficit of $274.8 million, cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million. For the nine months ended September 30, 2024, the Company had net loss of $3.0 million and net cash used in operations of $7.4 million. For the twelve months ended December 31, 2023, the Company had net losses of $14.0 million and net cash used in operations of $15.3 million.

With cash and cash equivalents of $3.9 million, short-term investments of $2.6 million and current note receivable of $1.8 million as of September 30, 2024, the Company believes that its existing cash, cash equivalents and short-term investments will not be sufficient to meet its anticipated cash requirements for at least the next 12-18 months from the issuance date of these financial statements, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The Company may seek to raise additional funds through debt or equity financings. The Company may also consider entering into additional partner arrangements. The sale of additional equity would result in dilution to the Company’s stockholders. The incurrence of debt would result in debt service obligations, and the instruments governing such debt could provide for additional operating and financing covenants that would restrict operations. If the Company requires additional funds and is unable to secure adequate additional funding at terms agreeable to the Company, the Company may be forced to reduce spending, extend payment terms with suppliers, liquidate assets, or suspend or curtail planned product launches. Any of these actions could materially harm the business, results of operations and financial condition.

Discontinued Operations

On May 16, 2024, the Company sold the GoodWheat brand to Above Food. GoodWheat operations ceased during the second quarter of 2024.

In July 2023, management made the decision to exit its body care brands as a result of continued pressure on the CBD market due to regulatory uncertainty. Body care operations ceased during the third quarter of 2023.

In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets and the results of the discontinued operations as separate components on the condensed consolidated statements of operations and comprehensive loss for all periods presented.

Major classes of line items constituting the balance sheet of discontinued operations:


	GoodWheat				Body Care
(In thousands)	September 30, 2024		December 31, 2023		September 30, 2024		December 31, 2023
Assets
Accounts receivable and other receivables	$	70	$	8	$	—	$	—
Inventories, net — current		—		1,121		—		—
Property and equipment, net		—		314		—		—
Inventories, net — noncurrent		—		3,158		—		—
Total assets	$	70	$	4,601	$	—	$	—

Liabilities
Accounts payable and accrued expenses	$	—	$	500	$	—	$	—
Total liabilities	$	—	$	500	$	—	$	—

Major classes of line items constituting net loss from discontinued operations:


	GoodWheat												Body Care

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended September 30,					Nine Months Ended September 30,
	2024			2023			2024			2023			2024		2023			2024		2023
(In thousands)
Product revenue	$	(76	)	$	300		$	372		$	484		$	—	$	37		$	—	$	373
Cost of revenues		—			(285	)		(691	)		(634	)		—		(34	)		—		(313	)
Research and development		—			(291	)		(400	)		(1,000	)		—		—			—		—
(Loss) Gain on sale of property and equipment		(24	)		11			65			36			—		—			—		—
Selling, general and administrative		(330	)		(1,580	)		(2,040	)		(4,551	)		—		(86	)		—		(651	)
Net loss from discontinued operations	$	(430	)	$	(1,845	)	$	(2,694	)	$	(5,665	)	$	—	$	(83	)	$	—	$	(591	)

The following table presents non-cash items of discontinued operations:


	GoodWheat						Body Care

	Nine Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2024			2023			2024		2023
Depreciation	$	37		$	109		$	—	$	24
Gain on disposal of property and equipment	$	(65	)	$	(36	)	$	—	$	—
Write-down of inventories	$	—		$	275		$	—	$	—
Accounts receivable and other receivables	$	(78	)	$	—		$	—	$	(99	)
Inventories	$	575		$	(1,975	)	$	—	$	250
Prepaid expenses and other current assets	$	—		$	—		$	—	$	14
Accounts payable and accrued expenses	$	(500	)	$	144		$	—	$	5
Proceeds from sale of property and equipment	$	342		$	37		$	—	$	—

There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023.

Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Assets at Fair Value
Total Assets at Fair Value	$ 5,410	$ 10,049
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	2,770	4,925
Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 2,640	$ 5,124
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]	Short-Term Investments [Member]
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	$ 5,410	$ 10,049
Level 1 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	2,770	4,925
Level 1 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 2,640	$ 5,124
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]	Short-Term Investments [Member]
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	$ 0	$ 0
Level 2 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 2 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 0	$ 0
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]	Short-Term Investments [Member]
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	$ 0	$ 0
Level 3 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments	$ 0	$ 0
Investment, Type [Extensible Enumeration]	Short-Term Investments [Member]	Short-Term Investments [Member]

Related-Party Transactions - Additional Information (Detail) - USD ($)	Sep. 30, 2024	Dec. 31, 2023
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due	$ 30,000	$ 58,000

Description of Business - Summary of Major Classes of Line Items Constituting the Balance Sheet on Discontinued Operations (Details) - Discontinued Operations [Member] - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member]
Assets
Accounts receivable and other receivables	$ 0	$ 0
Inventories, net - current	0	0
Property and equipment, net	0	0
Inventories, net - noncurrent	0	0
Total assets	0	0
Liabilities
Accounts payable and accrued expenses	0	0
Total liabilities	0	0
GoodWheat [Member]
Assets
Accounts receivable and other receivables	70	8
Inventories, net - current	0	1,121
Property and equipment, net	0	314
Inventories, net - noncurrent	0	3,158
Total assets	70	4,601
Liabilities
Accounts payable and accrued expenses	0	500
Total liabilities	$ 0	$ 500

Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 5,293	$ 9,948
Unrealized Gains	117	101
Unrealized Losses	0	0
Estimated Fair Value	5,410	10,049
Cash Equivalents [Member] \| Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,770	4,925
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	2,770	4,925
Short-term Investments [Member] \| Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	2,523	5,023
Unrealized Gains	117	101
Unrealized Losses	0	0
Estimated Fair Value	$ 2,640	$ 5,124

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (aaa)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 320
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481800/320-10-50-3

+ Details

Property and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2024

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	September 30, 2024			December 31, 2023
Software and computer equipment	$	291		$	349
Machinery and equipment		—			34
Furniture and fixtures		32			39
Leasehold improvements		1,584			1,590
Property and equipment, gross		1,907			2,012
Less: accumulated depreciation and amortization		(1,852	)		(1,942	)
Property and equipment, net	$	55		$	70

Property and Equipment, Net

9 Months Ended

Sep. 30, 2024

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

4. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	September 30, 2024			December 31, 2023
Software and computer equipment	$	291		$	349
Machinery and equipment		—			34
Furniture and fixtures		32			39
Leasehold improvements		1,584			1,590
Property and equipment, gross		1,907			2,012
Less: accumulated depreciation and amortization		(1,852	)		(1,942	)
Property and equipment, net	$	55		$	70

Depreciation expense was $7,000 and $92,000 for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $89,000 and $227,000 for the three and nine months ended September 30, 2023, respectively.

During the three and nine months ended September 30, 2024 and 2023, there were no sales of property and equipment from continuing operations.

Property and equipment are considered assets held for sale when management approves and commits to a plan to dispose of a property or group of properties. The property and equipment held for sale prior to the sale date is separately presented, within current assets, on the condensed consolidated balance sheet as assets held for sale.

Property and equipment related to Archipelago of $51,000 were classified as assets held for sale as of December 31, 2023. During the first quarter of 2024, the Company recorded an impairment of $36,000 related to these assets. During the second quarter of 2024, all Archipelago property and equipment previously held for sale were sold.

Warrants and Options (Tables)

9 Months Ended

Sep. 30, 2024

Warrants and Rights Note Disclosure [Abstract]

Summary of Warrants Issued to Purchase Common Stock

The Company issued the following warrants to purchase shares of its common stock, which are outstanding as of September 30, 2024 and December 31, 2023, respectively. These warrants are exercisable any time at the option of the holder until their expiration date.


	Issuance Date	Term	Exercise Price Per Share		Exercised during the Year Ended December 31, 2023			Outstanding at December 31, 2023		Exercised during the Nine Months Ended September 30, 2024			Outstanding at September 30, 2024
March 2023 Pre-Funded Warrants	March 2023	perpetual	$	—		(425,834	)		75,000		(75,000	)		—
December 2022 Service and Performance Warrants (1)	December 2022	5 years	$	11.20		—			1,000		—			1,000
October 2022 Service and Performance Warrants (1)	October 2022	5 years	$	16.00		—			1,000		—			1,000
August 2022 Pre-Funded Warrants	August 2022	perpetual	$	—		(56,813	)		—		—			—
January 2021 Placement Agent Warrants	January 2021	5.5 years	$	159.60		—			9,846		—			9,846
December 2020 Warrants (2)	December 2020	5.5 years	$	9.00		—			16,367		—			16,367
December 2020 Warrants	December 2020	5.5 years	$	120.00		—			49,100		—			49,100
December 2020 Placement Agent Warrants	December 2020	5 years	$	152.80		—			3,274		—			3,274
July 2020 Warrants (2)	July 2020	5.5 years	$	9.00		—			16,036		—			16,036
July 2020 Placement Agent Warrants	July 2020	5.5 years	$	198.80		—			802		—			802
May 2020 Warrants (2)	May 2020	5 years	$	9.00		—			9,946		—			9,946
May 2020 Warrants	May 2020	5 years	$	191.20		—			24,863		—			24,863
May 2020 Placement Agent Warrants	May 2020	5 years	$	245.20		—			1,741		—			1,741
September 2019 Placement Agent Warrants (3)	September 2019	5 years	$	379.20		—			1,649		—			—
June 2019 Placement Agent Warrants (3)	June 2019	5 years	$	251.60		—			1,862		—			—
April 2019 Service and Performance Warrants (1)(3)	April 2019	5 years	$	247.20		—			3,629		—			—
January 2021 Warrants (2)	January 2021	5.5 years	$	9.00		—			7,831		—			7,831
January 2021 Warrants	January 2021	5.5 years	$	125.20		—			90,629		—			90,629
September 2019 Warrants (2)	September 2019	5.5 years	$	9.00		—			9,892		—			9,892
September 2019 Warrants	September 2019	5.5 years	$	300.80		—			6,594		—			6,594
June 2019 Warrants	June 2019	5.5 years	$	200.00		—			10,896		—			10,896
Total						(482,647	)		341,957		(75,000	)		259,817

(1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities.

(2) These warrants were repriced as part of the March 2023 Private Placement offering.

(3) These warrants expired during the nine months ended September 30, 2024.

Summary of Key Terms and Activity of Liability Classified Preferred Investment Options

The key terms and activity of the liability classified preferred investment options are summarized as follows:


	Issuance Date	Term	Exercise Price Per Share		Exercised during the Year Ended December 31, 2023		Outstanding at December 31, 2023		Exercised during the Nine Months Ended September 30, 2024		Outstanding at September 30, 2024
March 2023 Options - Series A	March 2023	5 years	$	9.00		—		666,334		—		666,334
March 2023 Options - Series B (2)	March 2023	1.5 years	$	9.00		—		666,334		—		—
March 2023 Placement Agent Options	March 2023	5 years	$	11.25		—		33,317		—		33,317
August 2022 Options (1)	August 2022	5 years	$	9.00		—		118,063		—		118,063
August 2022 Placement Agent Options	August 2022	5 years	$	52.80		—		5,904		—		5,904
Total						—		1,489,952		—		823,618

(1) These options were repriced as part of the March 2023 Private Placement offering.

(2) These warrants expired during the nine months ended September 30, 2024.

Consolidated Joint Venture - Additional Information (Detail) - Archipelago Ventures Hawaii, LLC [Member] $ in Millions	Aug. 09, 2019 Individual	Sep. 30, 2024 USD ($)
Arcadia Biosciences, Inc [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		50.75%
Capital contributions \| $		$ 3.1
Legacy Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		49.25%
Capital contributions \| $		$ 3.0

- Definition

This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.

+ References + Details

Commitments and Contingencies - Additional Information (Detail) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($)	Dec. 31, 2010 USD ($) Program	Dec. 31, 2023 USD ($)	Jun. 30, 2005 USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability	$ 2,000		$ 2,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability		$ 3,000		$ 5,000
Date of merger and reorganization	Jun. 30, 2005
Number of development programs ceased \| Program		3
Number of development programs \| Program		6
Other noncurrent liability	$ 2,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract	1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements	2.00%
Minimum [Member] \| Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract	1 year
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract	5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements	15.00%
Maximum [Member] \| Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract	3 years

Commitment and Contingencies

9 Months Ended

Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

14. Commitments and Contingencies

Leases

The Company leases office and warehouse space and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 9.

Legal Matters

From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings.

Contingent Liability Related to the Anawah Acquisition

In June 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. During 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As of September 30, 2024, the Company continues to pursue or are otherwise liable for a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the condensed consolidated balance sheet as an other noncurrent liability.

Contracts

The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable.

The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements are or will be due.

The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company.

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	1,364,940	1,285,337
Common stock, outstanding	1,364,940	1,285,337

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Assets
Operating lease assets	$ 306		$ 306		$ 792
Total leased assets	306		306		792
Liabilities
Current - Operating	346		346		852
Noncurrent - Operating	0		0		155
Total leased liabilities	346		346		$ 1,007
Lease Cost
Net lease cost	$ 33	$ 83	$ 284	$ 253
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	8 months 12 days		8 months 12 days		2 years 3 months 18 days
Weighted-average discount rate	6.50%		6.50%		6.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 172	191	$ 678	572
Sublease income	(142)	(111)	(404)	(329)
SG&A Expenses [Member]
Lease Cost
Short term lease cost	$ 3	$ 3	$ 10	$ 10

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues:
Total revenues	$ 1,537	$ 1,298	$ 3,829	$ 3,677
Operating expenses :
Cost of revenues	1,032	818	2,136	1,996
Research and development	24	15	40	55
Gain on sale of intangible assets	0	0	(4,000)	0
Impairment of property and equipment	0	0	36	0
Selling, general and administrative	2,241	1,862	6,986	6,535
Total operating expenses	3,297	2,695	5,198	8,586
Loss from continuing operations	(1,760)	(1,397)	(1,369)	(4,909)
Interest income	233	133	428	538
Other income , net	15	17	168	36
Valuation loss on March 2023 PIPE	0	0	0	(6,076)
Change in fair value of common stock warrant and option liabilities	330	608	493	5,965
Issuance and offering costs allocated to liability classified options	0	0	0	(430)
Net loss from continuing operations before income taxes	(1,182)	(639)	(280)	(4,876)
Income tax provision	0	0	0	(1)
Net loss from continuing operations	(1,182)	(639)	(280)	(4,877)
Net loss	(1,612)	(2,567)	(2,974)	(11,133)
Net loss attributable to non-controlling interest	0	0	0	(5)
Net loss attributable to common stockholders	$ (1,612)	$ (2,567)	$ (2,974)	$ (11,128)
Net loss per share attributable to common stockholders:
Basic net loss per share attributable to common stockholders from continuing operations	$ (0.87)	$ (0.47)	$ (0.21)	$ (4.08)
Diluted net loss per share attributable to common stockholders from continuing operations	(0.87)	(0.47)	(0.21)	(4.08)
Basic net loss per share attributable to common stockholders from discontinued operations	(0.32)	(1.42)	(1.98)	(5.24)
Net loss per basic share attributable to common stockholders	(1.18)	(1.89)	(2.18)	(9.31)
Net loss per diluted share attributable to common stockholders	$ (1.18)	$ (1.89)	$ (2.18)	$ (9.31)
Weighted-average number of shares used in per share calculations:
Weighted average shares - Basic	1,363,753	1,359,511	1,362,754	1,195,354
Weighted average shares - Diluted	1,363,753	1,359,511	1,362,754	1,195,354
Other comprehensive income (loss), net of tax
Unrealized gains on available-for-sale securities	$ 36	$ 66	$ 117	$ 87
Reclassification adjustment for gains on available-for-sale securities included in net loss	0	0	(111)	0
Change in unrealized gains on available-for-sale securities	36	66	6	87
Comprehensive loss	(1,576)	(2,501)	(2,968)	(11,041)
Body Care
Operating expenses :
Net loss from discontinued operations	0	(83)	0	(591)
GoodWheat
Operating expenses :
Net loss from discontinued operations	(430)	(1,845)	(2,694)	(5,665)
Product
Revenues:
Total revenues	1,537	1,298	3,829	3,667
License
Revenues:
Total revenues	$ 0	$ 0	$ 0	$ 10

Note Receivable - Additional Information (Details) - USD ($)			3 Months Ended		9 Months Ended
	May 16, 2024	May 14, 2024	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accrued interest			$ 233,000	$ 133,000	$ 428,000	$ 538,000
Discontinued Operations [Member] \| GoodWheat [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Sale of net consideration	$ 3,700,000
Loss on sale of brand	$ 1,500
Payment to aquire promissory note		$ 2,000,000
Promissory note, current and non current.		$ 6,000,000
Promissory note term		3 years
Promissory note interest description		Wall Street Journal prime rate
Promissory note principal receviable each year		$ 2,000,000
Fair value of embedded derivative note receivable			250,000		250,000
Discounted promissory note			545,000		545,000
Amortization of discount			60,000		89,000
Accrued interest			$ 126,000		$ 193,000

Stock-Based Compensation and Employee Stock Purchase Program (Tables)

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Summary of Activity Under Stock Incentive Plans

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):


	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2023		80,078		$	85.30	$	—
Options granted		158,000			2.71		—
Options forfeited		(7,927	)		19.08	$	397
Options expired		(12,576	)		170.08		—
Outstanding — Balance at September 30, 2024		217,575		$	22.83	$	3,140
Vested and expected to vest — September 30, 2024		198,542		$	24.68	$	2,778
Exercisable — September 30, 2024		50,515		$	84.37	$	—

Weighted-Average Fair Value Assumption of Stock Option Awards

The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2024			2023		2024			2023
Expected term (years)		8.04			—		8.04			7.06
Expected volatility		101.31	%		—		101.31	%		124	%
Risk-free interest rate		3.77	%		—		3.77	%		3.61	%
Dividend yield		—			—		—			—

Description of Business and Basis of Presentation - Non-cash Items of Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Changes in operating assets and liabilities:
Inventories			$ 620	$ (1,388)
Prepaid expenses and other current assets			287	(284)
Accounts payable and accrued expenses			(719)	(300)
Proceeds from sale of property and equipment			342	42
Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] \| Discontinued Operations [Member]
Operating activities
Depreciation			0	24
Gain on sale of property and equipment	$ 0	$ 0	0	0
Write-down of inventories			0	0
Changes in operating assets and liabilities:
Accounts receivable and other receivables			0	(99)
Inventories			0	250
Prepaid expenses and other current assets			0	14
Accounts payable and accrued expenses			0	5
Proceeds from sale of property and equipment			0	0
GoodWheat [Member] \| Discontinued Operations [Member]
Operating activities
Depreciation			37	109
Gain on sale of property and equipment	$ 24	$ (11)	(65)	(36)
Write-down of inventories			0	275
Changes in operating assets and liabilities:
Accounts receivable and other receivables			(78)	0
Inventories			575	(1,975)
Prepaid expenses and other current assets			0	0
Accounts payable and accrued expenses			(500)	144
Proceeds from sale of property and equipment			$ 342	$ 37

Leases - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Jan. 31, 2024
Lessee Lease Description [Line Items]
Recognition of additional right-of-use asset and lease liability	$ 86,000
Existence of option to extend	true
Lease option to extend, description	Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. In January 2024, the Company exercised it's option to renew the facility lease in American Falls, Idaho for one year through December 31, 2024. The lease renewal resulted in recognition of additional right-of-use asset and lease liability of $86,000 on the condensed consolidated balance sheet. The Company subsequently terminated the facility lease in American Falls, Idaho effective July 2024.
Option to extend lease, term		1 year
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2024	Nov. 05, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		1,364,940
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	5950 Sherry Lane
Entity Address, Address Line Two	Suite 215
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75225
City Area Code	214
Local Phone Number	974-8921
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Stock-Based Compensation and Employee Stock Purchase Program

9 Months Ended

Sep. 30, 2024

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation and Employee Stock Purchase Program

12. Stock-Based Compensation and Employee Stock Purchase Program

Stock Incentive Plans

The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”).

In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 3,860 shares of common stock reserved for future issuance, which included 259 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The maximum number of shares that may be awarded to any individual employee, including our directors and officers, during any calendar year was 9,375 shares. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The exercise price for ISOs and NSOs will be granted at a price per share not less than the fair value of our common stock at the date of grant. Options granted generally vest over a four-year period; however, there might be alternative vesting schedules, as approved by the Board. Options granted, once vested, are generally exercisable for up to 10 years, after grant to the extent vested.

On June 25, 2024, the shareholders approved an amendment to the Company’s 2015 Plan that increased the number of shares of common stock that may be issued under the 2015 Plan by 200,000 shares and increased the maximum number of shares of common stock issuable to employees, including our officers and directors, in any fiscal year from 9,375 shares to 50,000 shares. On February 2, 2022, former president and chief executive officer of the Company, Stanley Jacot, Jr. was hired. The Company granted Mr. Jacot an inducement stock option to purchase 7,902 shares of the Company’s common stock pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Company filed a registration statement on Form S-8 to register the issuance of shares upon exercise of this inducement stock option. The inducement options grants were issued outside of the 2015 Plan, but are subject to the terms and conditions of the 2015 Plan. As of September 30, 2024, a total of 338,248 shares of common stock were reserved for issuance under the 2015 Plan, of which 127,725 shares of common stock are available for future grant. As of September 30, 2024, a total of 102 and 210,523 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2023, a total of 102 and 71,609 options were outstanding under the 2006 and 2015 Plans, respectively. A total of 6,949 and 8,366 inducement options were outstanding as of September 30, 2024 and December 31, 2023, respectively.

The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share):


	Shares Subject to Outstanding Options			Weighted- Average Exercise Price Per Share		Aggregate Intrinsic Value
Outstanding — Balance at December 31, 2023		80,078		$	85.30	$	—
Options granted		158,000			2.71		—
Options forfeited		(7,927	)		19.08	$	397
Options expired		(12,576	)		170.08		—
Outstanding — Balance at September 30, 2024		217,575		$	22.83	$	3,140
Vested and expected to vest — September 30, 2024		198,542		$	24.68	$	2,778
Exercisable — September 30, 2024		50,515		$	84.37	$	—

Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by its Board of Directors for each of the respective periods.

As of September 30, 2024, there was $524,000 of unrecognized compensation cost related to unvested stock-based compensation grants that will be recognized over the weighted-average remaining recognition period of 1.4 years.

In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine.

Expected Term—The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards.

Expected Volatility—The historical volatility data was computed using the daily closing prices for the Company’s shares during the equivalent period of the calculated expected term of the stock-based awards.

Risk-Free Interest Rate—The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted.

Expected Dividend—The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders.

The fair value of stock option awards was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumption:


	Three Months Ended September 30,					Nine Months Ended September 30,
	2024			2023		2024			2023
Expected term (years)		8.04			—		8.04			7.06
Expected volatility		101.31	%		—		101.31	%		124	%
Risk-free interest rate		3.77	%		—		3.77	%		3.61	%
Dividend yield		—			—		—			—

The Company recognized $155,000 and $395,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2024, respectively. The Company recognized $162,000 and $573,000 of compensation expense for stock options awards during the three and nine months ended September 30, 2023, respectively.

Employee Stock Purchase Plan

The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of September 30, 2024, the number of shares of common stock reserved for future issuance under the ESPP is 3,209. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of September 30, 2024, 8,073 shares had been issued under the ESPP. The Company recorded $2,000 and $6,000 of ESPP related compensation expense during the three and nine months ended September 30, 2024, respectively. The Company recorded $7,000 and $12,000 of ESPP related compensation expense during the three and nine months ended September 30, 2023, respectively.

Collaborative Arrangements

9 Months Ended

Sep. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborative Arrangements

8. Collaborative Arrangements

In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of our non-GMO RS durum wheat trait in North America. This collaborative arrangement was a contractual agreement with Corteva and involved a joint operating activity where both Arcadia and Corteva were active participants in the activities of the collaboration. Arcadia and Corteva participated in the research and development, and Arcadia had the primary responsibility for the intellectual property strategy while Corteva generally led the marketing and commercialization efforts. Both parties were exposed to significant risks and rewards of the collaboration and the agreement included both cost sharing and profit sharing. The activities were performed with no guarantee of either technological or commercial success.

The Company accounted for research and development (“R&D”) costs in accordance ASC 730, Research and Development, which states R&D costs must be charged to expense as incurred. Accordingly, internal R&D costs are expensed as incurred. Third-party R&D costs are expensed when the contracted work has been performed or as milestone results are achieved.

On May 14, 2024, the Company sold its RS durum wheat trait to Corteva. Under the terms of the agreement, Arcadia retained certain rights to use the RS durum wheat trait. The Company received $4.0 million in cash payment from Corteva during the nine months ended September 30, 2024 and recorded a gain of the same amount as the trait had no carrying value on the condensed consolidated statement of operations and comprehensive loss related to the transaction.

Net Loss per Share

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Net Loss per Share

15. Net Loss per Share

Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. Dilutive securities are not included in the computation of net loss per share when the impact would be anti-dilutive.

Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):


	Three Months Ended September 30,				For the Nine Months Ended September 30,
	2024		2023		2024		2023
Options to purchase common stock		217,575		84,058		217,575		84,058
Warrants to purchase common stock		259,817		266,957		259,817		266,957
Preferred investment options		823,618		1,489,952		823,618		1,489,952
Total		1,301,010		1,840,967		1,301,010		1,840,967

Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Shares Subject to Outstanding, Beginning Balance \| shares	80,078
Shares Subject to Outstanding, Options Granted \| shares	158,000
Shares Subject to Outstanding, Options Forfeited \| shares	(7,927)
Shares Subject to Outstanding, Options Expired \| shares	(12,576)
Shares Subject to Outstanding, Ending Balance \| shares	217,575
Shares Subject to Outstanding, Vested and expected to vest \| shares	198,542
Shares Subject to Outstanding, Exercisable \| shares	50,515
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance \| $ / shares	$ 85.30
Weighted-Average Exercise Price Per Share, Options granted \| $ / shares	2.71
Weighted-Average Exercise Price Per Share, Options forfeited \| $ / shares	19.08
Weighted-Average Exercise Price Per Share, Options expired \| $ / shares	170.08
Weighted Average Exercise Price Per Share, Outstanding Ending Balance \| $ / shares	22.83
Weighted Average Exercise Price Per Share, Vested and expected to vest \| $ / shares	24.68
Weighted Average Exercise Price Per Share, Exercisable \| $ / shares	$ 84.37
Aggregate Intrinsic Value, Beginning Balance \| $	$ 0
Aggregate Intrinsic Value, Options Granted \| $	0
Aggregate Intrinsic Value, Options Forfeited \| $	397
Aggregate Intrinsic Value, Options Expired \| $	0
Aggregate Intrinsic Value, Ending Balance \| $	3,140
Aggregate Intrinsic Value, Vested and expected to vest \| $	2,778
Aggregate Intrinsic Value, Exercisable \| $	$ 0

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (1,612)	$ (2,567)	$ (2,974)	$ (11,128)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Collaborative Arrangements - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Aug. 31, 2017	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Proceeds from sale of RS durum wheat trait				$ 4,000	$ 0
Gain on sale of collaborative arrangements		$ 0	$ 0	4,000	$ 0
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08
Proceeds from sale of RS durum wheat trait				4,000
Gain on sale of collaborative arrangements				$ 4,000

Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	8 years 14 days	0 years	8 years 14 days	7 years 21 days
Expected volatility	101.31%	0.00%	101.31%	124.00%
Risk-free interest rate	3.77%	0.00%	3.77%	3.61%
Dividend yield	0.00%	0.00%	0.00%	0.00%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Investments and Fair Value Instruments - Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Level 3 [Member]	Sep. 30, 2024	Dec. 31, 2023
Remaining Term [Member] \| March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	3 years 4 months 24 days	4 years 1 month 28 days
Remaining Term [Member] \| March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	0 years	7 months 9 days
Remaining Term [Member] \| August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Remaining term (in years)	2 years 11 months 1 day	3 years 8 months 1 day
Expected Volatility [Member] \| March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	86.9	91.7
Expected Volatility [Member] \| March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	78.7
Expected Volatility [Member] \| August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	91.8	90.5
Risk-Free Interest Rate [Member] \| March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	3.6	3.9
Risk-Free Interest Rate [Member] \| March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	5.2
Risk-Free Interest Rate [Member] \| August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	3.6	4
Expected Dividend Yield [Member] \| March 2023 Options - Series A & March 2023 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	0
Expected Dividend Yield [Member] \| March 2023 Options - Series B [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	0
Expected Dividend Yield [Member] \| August 2022 Options & August 2022 Placement Agent Options [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Preferred investment options liability, measurement input	0	0

Description of Business and Basis of Presentation - Summary of Major Classes of Line Items Constituting Net Loss from Discontinued Operations (Detail) - Discontinued Operations [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cost of revenues	$ 0	$ (34)	$ 0	$ (313)
Research and development	0	0	0	0
(Loss) Gain on sale of property and equipment	0	0	0	0
Selling, general and administrative	0	(86)	0	(651)
Net loss from discontinued operations	0	(83)	0	(591)
Co-packing business, Saavy Naturals, ProVault and Soul Spring Body Care Brands [Member] \| Product
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	0	37	0	373
GoodWheat [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cost of revenues	0	(285)	(691)	(634)
Research and development	0	(291)	(400)	(1,000)
(Loss) Gain on sale of property and equipment	(24)	11	65	36
Selling, general and administrative	(330)	(1,580)	(2,040)	(4,551)
Net loss from discontinued operations	(430)	(1,845)	(2,694)	(5,665)
GoodWheat [Member] \| Product
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue	$ (76)	$ 300	$ 372	$ 484

Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Securities Not Included in Diluted per Share Calculations

Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares):


	Three Months Ended September 30,				For the Nine Months Ended September 30,
	2024		2023		2024		2023
Options to purchase common stock		217,575		84,058		217,575		84,058
Warrants to purchase common stock		259,817		266,957		259,817		266,957
Preferred investment options		823,618		1,489,952		823,618		1,489,952
Total		1,301,010		1,840,967		1,301,010		1,840,967

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,936	$ 6,518
Short-term investments	2,640	5,124
Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of September 30, 2024 and December 31, 2023	882	506
Inventories - current	835	837
Assets held for sale	0	51
Note receivable - current	1,827	0
Prepaid expenses and other current assets	521	807
Current assets of discontinued operations - GoodWheat	70	1,129
Total current assets	10,711	14,972
Property and equipment, net	55	70
Right of use asset	306	792
Inventories - noncurrent	0	196
Intangible assets, net	39	39
Note receivable - noncurrent	3,966	0
Other noncurrent assets	164	164
Noncurrent assets of discontinued operations - GoodWheat	0	3,472
Total assets	15,241	19,705
Current liabilities:
Accounts payable and accrued expenses	1,692	1,910
Operating lease liability — current	346	852
Current liabilities of discontinued operations - GoodWheat	0	500
Total current liabilities	2,328	3,590
Operating lease liability — noncurrent	0	155
Common stock warrant and option liabilities	764	1,257
Other noncurrent liabilities	2,000	2,000
Total liabilities	5,092	7,002
Commitments and contingencies (Note 14)
Stockholders’ equity:
Common stock, $0.001 par value - 150,000,000 shares authorized; 1,364,940 and 1,285,337 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	65	65
Additional paid-in capital	284,919	284,515
Accumulated other comprehensive income	117	101
Accumulated deficit	(274,814)	(271,840)
Total stockholders' equity	10,287	12,841
Non-controlling interest	(138)	(138)
Total stockholders' equity	10,149	12,703
Total liabilities and stockholders’ equity	15,241	19,705
Related Party [Member]
Current liabilities:
Other current liabilities	30	58
Nonrelated Party [Member]
Current liabilities:
Other current liabilities	$ 260	$ 270

Investments and Fair Value Instruments - Additional Information (Detail)	Sep. 30, 2024 USD ($)
Investments, Debt and Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
Inventory - Additional Information (Detail) - USD ($)	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Inventory [Line Items]
Write-down of inventories	$ 154,000	$ 252,000	$ 154,000	$ 444,000

Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities (Detail) - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 3,257
Initial recognition	250
Change in fair value	(493)
Ending Balance	3,014
March 2023 Options - Series A [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	1,008
Initial recognition	0
Change in fair value	(378)
Ending Balance	630
March 2023 Options - Series B [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	41
Initial recognition	0
Change in fair value	(41)
Ending Balance	0
March 2023 Placement Agent Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	46
Initial recognition	0
Change in fair value	(19)
Ending Balance	27
August 2022 Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	159
Initial recognition	0
Change in fair value	(53)
Ending Balance	106
August 2022 Placement Agent Options [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	3
Initial recognition	0
Change in fair value	(2)
Ending Balance	1
Note Receivable Bifurcated Derivatives [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0
Initial recognition	250
Change in fair value	0
Ending Balance	250
Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,000
Initial recognition	0
Change in fair value	0
Ending Balance	$ 2,000

Investments and Fair Value Instruments

9 Months Ended

Sep. 30, 2024

Investments And Fair Value Instruments [Abstract]

Investments and Fair Value Instruments

5. Investments and Fair Value Instruments

Available-for-Sale Investments

The Company classified short-term investments as “available-for-sale.” These short-term investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses are included in accumulated other comprehensive income, which is reflected as a separate component of stockholder’s equity in the condensed consolidated balance sheets. Gains and losses are recognized when realized in the condensed consolidated statements of operations and comprehensive loss.

The following tables summarize the amortized cost and fair value of the investment securities portfolio at September 30, 2024 and December 31, 2023 and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income:


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
September 30, 2024
Cash equivalents:
Money market funds	$	2,770	$	—	$	—	$	2,770
Short-term investments:
Treasury bills		2,523		117		—		2,640
Total Assets at Fair Value	$	5,293	$	117	$	—	$	5,410


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
December 31, 2023
Cash equivalents:
Money market funds	$	4,925	$	—	$	—	$	4,925
Short-term investments:
Treasury bills		5,023		101		—	$	5,124
Total Assets at Fair Value	$	9,948	$	101	$	—	$	10,049

The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of September 30, 2024.

Fair Value Measurement

The fair value of the investment securities at September 30, 2024 were as follows:


	Fair Value Measurements at September 30, 2024
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	2,770	$	—	$	—	$	2,770
Short-term investments:
Treasury bills		2,640		—		—		2,640
Total Assets at Fair Value	$	5,410	$	—	$	—	$	5,410

The fair value of the investment securities at December 31, 2023 were as follows:


	Fair Value Measurements at December 31, 2023
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	4,925	$	—	$	—	$	4,925
Short-term investments:
Treasury bills		5,124		—		—		5,124
Total Assets at Fair Value	$	10,049	$	—	$	—	$	10,049

The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2024 or 2023. The Company’s financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable and other receivables, note receivable, accounts payable and accrued liabilities. For short-term investments, accounts receivable and other receivables, accounts payable and accrued liabilities, the carrying amounts of these financial instruments as of September 30, 2024 and December 31, 2023 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The note receivable is recorded at amortized cost. The amortized cost of the note receivable is considered approximate fair value due to its variable interest rate.

The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah, Inc. ("Anawah") acquisition as described in Note 14, as well as preferred investment options related to the March 2023 Private Placement and August 2022 Registered Direct offerings described in Note 10.

The contingent liability related to the Anawah acquisition was measured and recorded on a recurring basis as of September 30, 2024 and December 31, 2023, using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase. A significant deviation in the Company’s ability and/or intent to pursue the technology acquired in the purchase could result in a significantly lower (higher) fair value measurement.

The preferred investment option liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions as of September 30, 2024 and December 31, 2023:


	March 2023 Options - Series A & March 2023 Placement Agent Options						March 2023 Options - Series B					August 2022 Options & August 2022 Placement Agent Options
	September 30, 2024			December 31, 2023			September 30, 2024		December 31, 2023			September 30, 2024			December 31, 2023
Remaining term (in years)		3.40			4.16			—		0.61			2.92			3.67
Expected volatility		86.9	%		91.7	%		—		78.7	%		91.8	%		90.5	%
Risk-free interest rate		3.6	%		3.9	%		—		5.2	%		3.6	%		4.0	%
Expected dividend yield		0	%		0	%		—		0	%		0	%		0	%

The significant input used in the fair value measurement of the Company’s Level 3 options liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement.

The following table sets forth the establishment of the Company’s Level 3 assets and liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands):



(Dollars in thousands)	March 2023 Options - Series A			March 2023 Options - Series B			March 2023 Placement Agent Options			August 2022 Options			August 2022 Placement Agent Options			Note Receivable Bifurcated Derivatives		Contingent Liabilities		Total
Balance as of December 31, 2023	$	1,008		$	41		$	46		$	159		$	3		$	—	$	2,000	$	3,257
Initial recognition		—			—			—			—			—			250		—		250
Change in fair value		(378	)		(41	)		(19	)		(53	)		(2	)		—		—		(493	)
Balance as of September 30, 2024	$	630		$	—		$	27		$	106		$	1		$	250	$	2,000	$	3,014

Equity Financing - Additional Information (Detail) - USD ($)		1 Months Ended	9 Months Ended
	Mar. 06, 2023	Mar. 31, 2023	Sep. 30, 2024	Aug. 31, 2022	Jan. 31, 2021	Dec. 31, 2020	Jul. 31, 2020	May 31, 2020	Sep. 30, 2019
Common Stock and Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Remaining offering costs allocated to common stock and offset to additional paid in capital	$ 330,000
March 2023 Placement Agent Options [Member]
Class Of Warrant Or Right [Line Items]
Issuance costs allocated to liability preferred options	$ 430,000
March 2023 Options and March 2023 Placement Agent Options [Member]
Class Of Warrant Or Right [Line Items]
Expected volatility	128.55%
Stock price	$ 7.61
Risk-free interest rate	4.27%
March 2023 Options and March 2023 Placement Agent Options [Member] \| Series B Preferred Investment Options [Member]
Class Of Warrant Or Right [Line Items]
Expected volatility	103.33%
Stock price	$ 7.61
Risk-free interest rate	4.97%
March 2023 Options [Member]
Class Of Warrant Or Right [Line Items]
Estimated fair value of liability options	$ 6,600,000
March 2023 Private Placement [Member] \| March 2023 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		165,500
Offering costs			$ 548,000
March 2023 Private Placement [Member] \| March 2023 Purchase Agreement [Member] \| Pre Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		500,834
Warrants issued, exercise price		$ 0.0001
March 2023 Private Placement [Member] \| March 2023 Purchase Agreement [Member] \| Common Stock and Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Fair value of common stock and pre-funded warrants	5,100,000
March 2023 Private Placement [Member] \| Series A Preferred Investment Options [Member] \| March 2023 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		666,334
Exercise price		$ 9
Options expiration period		5 years
March 2023 Private Placement [Member] \| Series A and B Preferred Investment Options [Member] \| March 2023 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		666,334
Exercise price		$ 9
Proceeds from issuance of common stock and warrants gross			6,000,000
March 2023 Private Placement [Member] \| Series B Preferred Investment Options [Member] \| March 2023 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Options expiration period		1 year 6 months
March 2023 Private Placement [Member] \| March 2023 Placement Agent Options [Member] \| Preferred Investment Options [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		33,317
March 2023 Private Placement [Member] \| March 2023 Placement Agent Options [Member] \| March 2023 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Common stock options issued to placement agent and included in offering costs			212,000
March 2023 Private Placement [Member] \| March 2023 Placement Agent Options [Member] \| March 2023 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant modification included in valuation loss			404,000
March 2023 Private Placement [Member] \| August 2022 Placement Agent Options [Member] \| August 2022 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant modification included in valuation loss			$ 185,000
March 2023 Private Placement [Member] \| March 2023 Options [Member] \| March 2023 Purchase Agreement [Member] \| Common Stock and Pre-Funded Warrants [Member]
Class Of Warrant Or Right [Line Items]
Estimated fair value, loss	$ 5,700,000
March 2023 Private Placement [Member] \| Option Amendment Agreements [Member] \| Preferred Investment Options [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		178,132
March 2023 Private Placement [Member] \| Option Amendment Agreements [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price		$ 9		$ 37.35	$ 125.2	$ 120	$ 154	$ 191	$ 300.8
March 2023 Private Placement [Member] \| Option Amendment Agreements [Member] \| March 2023 Placement Agent Options [Member]
Class Of Warrant Or Right [Line Items]
Exercise price			$ 11.25
Warrant, exercisable term			5 years

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Federal statutory tax rate			21.00%
Effective tax rate	0.00%	0.00%	0.00%	0.00%
Uncertain tax positions	$ 0		$ 0

Description of Business and Basis of Presentation (Tables)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Summary of Major Classes of Line Items Constituting Discontinued Operations

Major classes of line items constituting the balance sheet of discontinued operations:


	GoodWheat				Body Care
(In thousands)	September 30, 2024		December 31, 2023		September 30, 2024		December 31, 2023
Assets
Accounts receivable and other receivables	$	70	$	8	$	—	$	—
Inventories, net — current		—		1,121		—		—
Property and equipment, net		—		314		—		—
Inventories, net — noncurrent		—		3,158		—		—
Total assets	$	70	$	4,601	$	—	$	—

Liabilities
Accounts payable and accrued expenses	$	—	$	500	$	—	$	—
Total liabilities	$	—	$	500	$	—	$	—

Major classes of line items constituting net loss from discontinued operations:


	GoodWheat												Body Care

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended September 30,					Nine Months Ended September 30,
	2024			2023			2024			2023			2024		2023			2024		2023
(In thousands)
Product revenue	$	(76	)	$	300		$	372		$	484		$	—	$	37		$	—	$	373
Cost of revenues		—			(285	)		(691	)		(634	)		—		(34	)		—		(313	)
Research and development		—			(291	)		(400	)		(1,000	)		—		—			—		—
(Loss) Gain on sale of property and equipment		(24	)		11			65			36			—		—			—		—
Selling, general and administrative		(330	)		(1,580	)		(2,040	)		(4,551	)		—		(86	)		—		(651	)
Net loss from discontinued operations	$	(430	)	$	(1,845	)	$	(2,694	)	$	(5,665	)	$	—	$	(83	)	$	—	$	(591	)

The following table presents non-cash items of discontinued operations:


	GoodWheat						Body Care

	Nine Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2024			2023			2024		2023
Depreciation	$	37		$	109		$	—	$	24
Gain on disposal of property and equipment	$	(65	)	$	(36	)	$	—	$	—
Write-down of inventories	$	—		$	275		$	—	$	—
Accounts receivable and other receivables	$	(78	)	$	—		$	—	$	(99	)
Inventories	$	575		$	(1,975	)	$	—	$	250
Prepaid expenses and other current assets	$	—		$	—		$	—	$	14
Accounts payable and accrued expenses	$	(500	)	$	144		$	—	$	5
Proceeds from sale of property and equipment	$	342		$	37		$	—	$	—

There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023.

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

+ Details

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 450	$ 373
Finished goods	385	660
Inventories	$ 835	$ 1,033

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,907	$ 2,012
Less accumulated depreciation and amortization	(1,852)	(1,942)
Property and equipment, net	55	70
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	291	349
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	0	34
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	32	39
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,584	$ 1,590

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business and Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Organization

On May 16, 2024, the Company sold the GoodWheat™ brand to Above Food Ingredients Corp. ("Above Food") for net consideration of $3.7 million. Refer to Note 6 for details of the transaction.

Basis of Presentation and Principles of Consolidation

Reclassifications

Reverse Stock Split

Liquidity, Capital Resources, and Going Concern

Discontinued Operations

On May 16, 2024, the Company sold the GoodWheat brand to Above Food. GoodWheat operations ceased during the second quarter of 2024.

Major classes of line items constituting the balance sheet of discontinued operations:


	GoodWheat				Body Care
(In thousands)	September 30, 2024		December 31, 2023		September 30, 2024		December 31, 2023
Assets
Accounts receivable and other receivables	$	70	$	8	$	—	$	—
Inventories, net — current		—		1,121		—		—
Property and equipment, net		—		314		—		—
Inventories, net — noncurrent		—		3,158		—		—
Total assets	$	70	$	4,601	$	—	$	—

Liabilities
Accounts payable and accrued expenses	$	—	$	500	$	—	$	—
Total liabilities	$	—	$	500	$	—	$	—

Major classes of line items constituting net loss from discontinued operations:


	GoodWheat												Body Care

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended September 30,					Nine Months Ended September 30,
	2024			2023			2024			2023			2024		2023			2024		2023
(In thousands)
Product revenue	$	(76	)	$	300		$	372		$	484		$	—	$	37		$	—	$	373
Cost of revenues		—			(285	)		(691	)		(634	)		—		(34	)		—		(313	)
Research and development		—			(291	)		(400	)		(1,000	)		—		—			—		—
(Loss) Gain on sale of property and equipment		(24	)		11			65			36			—		—			—		—
Selling, general and administrative		(330	)		(1,580	)		(2,040	)		(4,551	)		—		(86	)		—		(651	)
Net loss from discontinued operations	$	(430	)	$	(1,845	)	$	(2,694	)	$	(5,665	)	$	—	$	(83	)	$	—	$	(591	)

The following table presents non-cash items of discontinued operations:


	GoodWheat						Body Care

	Nine Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2024			2023			2024		2023
Depreciation	$	37		$	109		$	—	$	24
Gain on disposal of property and equipment	$	(65	)	$	(36	)	$	—	$	—
Write-down of inventories	$	—		$	275		$	—	$	—
Accounts receivable and other receivables	$	(78	)	$	—		$	—	$	(99	)
Inventories	$	575		$	(1,975	)	$	—	$	250
Prepaid expenses and other current assets	$	—		$	—		$	—	$	14
Accounts payable and accrued expenses	$	(500	)	$	144		$	—	$	5
Proceeds from sale of property and equipment	$	342		$	37		$	—	$	—

There were no other operating or investing non-cash items for the nine months ended September 30, 2024 and 2023.

Warrants and Options

9 Months Ended

Sep. 30, 2024

Warrants and Rights Note Disclosure [Abstract]

Warrants and Options

11. Warrants and Options

Equity Classified Common Stock Warrants


	Issuance Date	Term	Exercise Price Per Share		Exercised during the Year Ended December 31, 2023			Outstanding at December 31, 2023		Exercised during the Nine Months Ended September 30, 2024			Outstanding at September 30, 2024
March 2023 Pre-Funded Warrants	March 2023	perpetual	$	—		(425,834	)		75,000		(75,000	)		—
December 2022 Service and Performance Warrants (1)	December 2022	5 years	$	11.20		—			1,000		—			1,000
October 2022 Service and Performance Warrants (1)	October 2022	5 years	$	16.00		—			1,000		—			1,000
August 2022 Pre-Funded Warrants	August 2022	perpetual	$	—		(56,813	)		—		—			—
January 2021 Placement Agent Warrants	January 2021	5.5 years	$	159.60		—			9,846		—			9,846
December 2020 Warrants (2)	December 2020	5.5 years	$	9.00		—			16,367		—			16,367
December 2020 Warrants	December 2020	5.5 years	$	120.00		—			49,100		—			49,100
December 2020 Placement Agent Warrants	December 2020	5 years	$	152.80		—			3,274		—			3,274
July 2020 Warrants (2)	July 2020	5.5 years	$	9.00		—			16,036		—			16,036
July 2020 Placement Agent Warrants	July 2020	5.5 years	$	198.80		—			802		—			802
May 2020 Warrants (2)	May 2020	5 years	$	9.00		—			9,946		—			9,946
May 2020 Warrants	May 2020	5 years	$	191.20		—			24,863		—			24,863
May 2020 Placement Agent Warrants	May 2020	5 years	$	245.20		—			1,741		—			1,741
September 2019 Placement Agent Warrants (3)	September 2019	5 years	$	379.20		—			1,649		—			—
June 2019 Placement Agent Warrants (3)	June 2019	5 years	$	251.60		—			1,862		—			—
April 2019 Service and Performance Warrants (1)(3)	April 2019	5 years	$	247.20		—			3,629		—			—
January 2021 Warrants (2)	January 2021	5.5 years	$	9.00		—			7,831		—			7,831
January 2021 Warrants	January 2021	5.5 years	$	125.20		—			90,629		—			90,629
September 2019 Warrants (2)	September 2019	5.5 years	$	9.00		—			9,892		—			9,892
September 2019 Warrants	September 2019	5.5 years	$	300.80		—			6,594		—			6,594
June 2019 Warrants	June 2019	5.5 years	$	200.00		—			10,896		—			10,896
Total						(482,647	)		341,957		(75,000	)		259,817

(1) The Company issued service and performance warrants (“Service and Performance Warrants”) in connection with professional services agreements with non-affiliated third party entities.

(2) These warrants were repriced as part of the March 2023 Private Placement offering.

(3) These warrants expired during the nine months ended September 30, 2024.

Liability Classified Preferred Investment Options

The preferred investment options issued in connection with the March 2023 Private Placement and August 2022 Registered Direct offerings contain certain early settlement provisions that preclude them from equity classification and therefore were accounted for as liabilities at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the options liabilities is recorded as change in fair value of common stock warrant and option liabilities in the condensed consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified preferred investment options are summarized as follows:


	Issuance Date	Term	Exercise Price Per Share		Exercised during the Year Ended December 31, 2023		Outstanding at December 31, 2023		Exercised during the Nine Months Ended September 30, 2024		Outstanding at September 30, 2024
March 2023 Options - Series A	March 2023	5 years	$	9.00		—		666,334		—		666,334
March 2023 Options - Series B (2)	March 2023	1.5 years	$	9.00		—		666,334		—		—
March 2023 Placement Agent Options	March 2023	5 years	$	11.25		—		33,317		—		33,317
August 2022 Options (1)	August 2022	5 years	$	9.00		—		118,063		—		118,063
August 2022 Placement Agent Options	August 2022	5 years	$	52.80		—		5,904		—		5,904
Total						—		1,489,952		—		823,618

(1) These options were repriced as part of the March 2023 Private Placement offering.

(2) These warrants expired during the nine months ended September 30, 2024.

Investments and Fair Value Instruments (Tables)

9 Months Ended

Sep. 30, 2024

Investments And Fair Value Instruments [Abstract]

Summary of Amortized Cost and Fair Value of Investment Securities Portfolio


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
September 30, 2024
Cash equivalents:
Money market funds	$	2,770	$	—	$	—	$	2,770
Short-term investments:
Treasury bills		2,523		117		—		2,640
Total Assets at Fair Value	$	5,293	$	117	$	—	$	5,410


(Dollars in thousands)	Amortized Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value
December 31, 2023
Cash equivalents:
Money market funds	$	4,925	$	—	$	—	$	4,925
Short-term investments:
Treasury bills		5,023		101		—	$	5,124
Total Assets at Fair Value	$	9,948	$	101	$	—	$	10,049

Summary of Fair Value of Investment Securities

The fair value of the investment securities at September 30, 2024 were as follows:


	Fair Value Measurements at September 30, 2024
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	2,770	$	—	$	—	$	2,770
Short-term investments:
Treasury bills		2,640		—		—		2,640
Total Assets at Fair Value	$	5,410	$	—	$	—	$	5,410

The fair value of the investment securities at December 31, 2023 were as follows:


	Fair Value Measurements at December 31, 2023
(Dollars in thousands)	Level 1		Level 2		Level 3		Total
Assets at Fair Value
Cash equivalents:
Money market funds	$	4,925	$	—	$	—	$	4,925
Short-term investments:
Treasury bills		5,124		—		—		5,124
Total Assets at Fair Value	$	10,049	$	—	$	—	$	10,049

Summary of Preferred Investment Option Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model


	March 2023 Options - Series A & March 2023 Placement Agent Options						March 2023 Options - Series B					August 2022 Options & August 2022 Placement Agent Options
	September 30, 2024			December 31, 2023			September 30, 2024		December 31, 2023			September 30, 2024			December 31, 2023
Remaining term (in years)		3.40			4.16			—		0.61			2.92			3.67
Expected volatility		86.9	%		91.7	%		—		78.7	%		91.8	%		90.5	%
Risk-free interest rate		3.6	%		3.9	%		—		5.2	%		3.6	%		4.0	%
Expected dividend yield		0	%		0	%		—		0	%		0	%		0	%

Summary of Changes in Fair Value and Other Adjustments of Assets and Liabilities

The following table sets forth the establishment of the Company’s Level 3 assets and liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands):



(Dollars in thousands)	March 2023 Options - Series A			March 2023 Options - Series B			March 2023 Placement Agent Options			August 2022 Options			August 2022 Placement Agent Options			Note Receivable Bifurcated Derivatives		Contingent Liabilities		Total
Balance as of December 31, 2023	$	1,008		$	41		$	46		$	159		$	3		$	—	$	2,000	$	3,257
Initial recognition		—			—			—			—			—			250		—		250
Change in fair value		(378	)		(41	)		(19	)		(53	)		(2	)		—		—		(493	)
Balance as of September 30, 2024	$	630		$	—		$	27		$	106		$	1		$	250	$	2,000	$	3,014

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	March 2023 PIPE [Member]	Common Stock [Member]	Common Stock [Member] August 2022 Pre-Funded Warrants [Member]	Common Stock [Member] March 2023 Pre-Funded Warrants [Member]	Common Stock [Member] March 2023 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] March 2023 PIPE [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Non-Controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2022	$ 20,900		$ 65				$ 278,827		$ (257,859)		$ (133)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2022			616,079
Issuance of shares		$ 4,740						$ 4,740
Issuance of shares, Shares						165,500
Modification of warrants related to March 2023 PIPE		$ 219						$ 219
Issuance of shares related to Pre-Funded Warrants exercise				56,813
Issuance of shares related to employee stock purchase plan	5						5
Issuance of shares related to employee stock purchase plan, Shares			88
Issuance of shares related to reverse stock split			19,092
Stock-based compensation	212						212
Net (loss) income	(9,384)								(9,384)
Stockholders Equity, Ending Balance at Mar. 31, 2023	16,692		$ 65				284,003		(267,243)		(133)
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2023			857,572
Stockholders Equity, Beginning Balance at Dec. 31, 2022	$ 20,900		$ 65				278,827		(257,859)		(133)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2022			616,079
Issuance of shares related to Pre-Funded Warrants exercise	(482,647)
Net (loss) income	$ (11,133)
Stockholders Equity, Ending Balance at Sep. 30, 2023	15,398		$ 65				284,371		(268,987)	$ 87	(138)
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2023			1,110,337
Stockholders Equity, Beginning Balance at Dec. 31, 2022	20,900		$ 65				278,827		(257,859)		(133)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2022			616,079
Net (loss) income	(14,000)
Stockholders Equity, Ending Balance at Dec. 31, 2023	12,703		$ 65				284,515		(271,840)	101	(138)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2023			1,285,337
Stockholders Equity, Beginning Balance at Mar. 31, 2023	16,692		$ 65				284,003		(267,243)		(133)
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2023			857,572
Issuance of shares related to Pre-Funded Warrants exercise					250,834
Issuance of shares related to reverse stock split			26
Stock-based compensation	199						199
Change in unrealized gains on available-for-sale securities	21									21
Net (loss) income	818								823		(5)
Stockholders Equity, Ending Balance at Jun. 30, 2023	17,730		$ 65				284,202		(266,420)	21	(138)
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2023			1,108,432
Issuance of shares related to employee stock purchase plan	7						7
Issuance of shares related to employee stock purchase plan, Shares			1,905
Stock-based compensation	162						162
Change in unrealized gains on available-for-sale securities	66									66
Net (loss) income	(2,567)								(2,567)
Stockholders Equity, Ending Balance at Sep. 30, 2023	15,398		$ 65				284,371		(268,987)	87	(138)
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2023			1,110,337
Stockholders Equity, Beginning Balance at Dec. 31, 2023	12,703		$ 65				284,515		(271,840)	101	(138)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2023			1,285,337
Issuance of shares related to Pre-Funded Warrants exercise					75,000
Issuance of shares related to employee stock purchase plan	5						5
Issuance of shares related to employee stock purchase plan, Shares			2,503
Stock-based compensation	138						138
Change in unrealized gains on available-for-sale securities	60									60
Net (loss) income	(2,423)								(2,423)
Stockholders Equity, Ending Balance at Mar. 31, 2024	10,483		$ 65				284,658		(274,263)	161	(138)
Stockholders Equity, Ending Balance, Shares at Mar. 31, 2024			1,362,840
Stockholders Equity, Beginning Balance at Dec. 31, 2023	$ 12,703		$ 65				284,515		(271,840)	101	(138)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2023			1,285,337
Issuance of shares related to Pre-Funded Warrants exercise	(75,000)
Issuance of shares related to reverse stock split	19,118
Net (loss) income	$ (2,974)
Stockholders Equity, Ending Balance at Sep. 30, 2024	10,149		$ 65				284,919		(274,814)	117	(138)
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2024			1,364,940
Stockholders Equity, Beginning Balance at Mar. 31, 2024	10,483		$ 65				284,658		(274,263)	161	(138)
Stockholders Equity, Beginning Balance, Shares at Mar. 31, 2024			1,362,840
Stock-based compensation	102						102
Change in unrealized gains on available-for-sale securities	(80)									(80)
Net (loss) income	1,061								1,061
Stockholders Equity, Ending Balance at Jun. 30, 2024	11,566		$ 65				284,760		(273,202)	81	(138)
Stockholders Equity, Ending Balance, Shares at Jun. 30, 2024			1,362,840
Issuance of shares related to employee stock purchase plan	4						4
Issuance of shares related to employee stock purchase plan, Shares			2,100
Stock-based compensation	155						155
Change in unrealized gains on available-for-sale securities	36									36
Net (loss) income	(1,612)								(1,612)
Stockholders Equity, Ending Balance at Sep. 30, 2024	$ 10,149		$ 65				$ 284,919		$ (274,814)	$ 117	$ (138)
Stockholders Equity, Ending Balance, Shares at Sep. 30, 2024			1,364,940

Recent Accounting Pronouncements

9 Months Ended

Sep. 30, 2024

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

2. Recent Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280) — Improvements to Reportable Segment Disclosures. The amendments in this update improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The new guidance is effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our segment disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) — Improvements to Income Tax Disclosures. The amendments in this update require additional income tax disclosures primarily related to the rate reconciliation and income taxes paid. The new guidance is effective either prospectively or retrospectively, for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this update on our income tax disclosures.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476173/280-10-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483550/848-10-65-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483194/926-20-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org/250/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

+ Details

Leases

9 Months Ended

Sep. 30, 2024

Lessee Disclosure [Abstract]

Leases

9. Leases

Operating Leases

As of September 30, 2024, the Company leases office space in Dallas, TX, Davis and Sacramento, CA, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases the Davis office to third parties.

Some leases (the Dallas and Davis offices, a warehouse, and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. In January 2024, the Company exercised it's option to renew the facility lease in American Falls, Idaho for one year through December 31, 2024. The lease renewal resulted in recognition of additional right-of-use asset and lease liability of $86,000 on the condensed consolidated balance sheet. The Company subsequently terminated the facility lease in American Falls, Idaho effective July 2024.

The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands):


Leases	Classification	September 30, 2024		December 31, 2023
Assets
Operating lease assets	Right of use asset	$	306	$	792
Total leased assets		$	306	$	792
Liabilities
Current - Operating	Operating lease liability- current	$	346	$	852
Noncurrent - Operating	Operating lease liability- noncurrent		—		155
Total leased liabilities		$	346	$	1,007


Lease Cost	Classification	Three Months Ended September 30, 2024			Three Months Ended September 30, 2023			Nine Months Ended September 30, 2024			Nine Months Ended September 30, 2023
Operating lease cost	SG&A and R&D Expenses	$	172		$	191		$	678		$	572
Short term lease cost	SG&A Expenses		3			3			10			10
Sublease income (1)	SG&A and R&D Expenses		(142	)		(111	)		(404	)		(329	)
Net lease cost		$	33		$	83		$	284		$	253

(1)

Sublease income is recorded as a reduction to lease expense.


Lease Term and Discount Rate	September 30, 2024			December 31, 2023
Weighted-average remaining lease term (years)		0.7			2.3
Weighted-average discount rate		6.5	%		6.0	%

Inventory

9 Months Ended

Sep. 30, 2024

Inventory Disclosure [Abstract]

Inventory

3. Inventory

Inventory costs are tracked on a lot-identified basis and are included as cost of revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of revenues and are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded a write-down of $154,000 related to hemp and GoodWheat seed during the three and nine months ended September 30, 2024. The Company recorded inventory write-downs of $252,000 and $444,000 related to packaging materials, hemp seed and GoodWheat during the three and nine months ended September 30, 2023, respectively. If there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase the Company’s expenses in the period the write down is taken and materially affect the Company’s operating results.

Inventories, net consist of the following (in thousands):


	September 30, 2024		December 31, 2023
Raw materials	$	450	$	373
Finished goods		385		660
Inventories	$	835	$	1,033